Strategic investor and operating executive focused on growth-stage consumer and fintech companies. Marilou Davido brings operating leadership across product, go-to-market and partnerships, with experience scaling teams, raising institutional capital and managing M&A processes. Known for data-driven commercial strategy and board-level governance, she often advises founders on customer acquisition and unit economics. Active in seed to Series B rounds and corporate venture initiatives, she combines hands-on operating skills with investor relations experience.
Strategic investor and operating executive focused on growth-stage consumer and fintech companies. Marilou Davido brings operating leadership across product, go-to-market and partnerships, with experience scaling teams, raising institutional capital and managing M&A processes. Known for data-driven commercial strategy and board-level governance, she often advises founders on customer acquisition and unit economics. Active in seed to Series B rounds and corporate venture initiatives, she combines hands-on operating skills with investor relations experience.
Focused on growth-stage consumer and fintech deals, she blends hands-on operating instincts with early-stage investing, targeting seed to Series B opportunities where product-market fit is clear and unit economics can scale. Investment selection emphasizes data-driven customer acquisition, partnership-led distribution, and repeatable revenue models. Capital allocation favors concentrated small bets with reserve for follow-ons, active board or adviser roles, and a 3–7 year horizon to drive commercialization, margin expansion and exit through strategic sale or growth equity rounds.
Focused on growth-stage consumer and fintech deals, she blends hands-on operating instincts with early-stage investing, targeting seed to Series B opportunities where product-market fit is clear and unit economics can scale. Investment selection emphasizes data-driven customer acquisition, partnership-led distribution, and repeatable revenue models. Capital allocation favors concentrated small bets with reserve for follow-ons, active board or adviser roles, and a 3–7 year horizon to drive commercialization, margin expansion and exit through strategic sale or growth equity rounds.
| Trades 2458 | Longs Won 1661/2458 67% | Profit Factor 8.68 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $240,305.37 |
| Average Win $50,596.42 | Best Trade (Oct 15) $5.67M | Sharpe Ratio -10.77 |
| Average Loss -$12,151.98 | Worst Trade (Dec 31) -$1.54M | Z-Score 23.45 (100%) |
| Commissions $0 | Avg. Trade Length 2y 2m 4d | Expectancy $30,250.42 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 17,857 | 16,071 | 14,286 | 12,500 | 10,714 | 8,929 | 7,143 | 5,357 | 3,571 | 1,786 |
| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
AAPL Apple Inc. | 34,161 | $6.16M | $11.81M | - | $5.65M | 91.71% | +1.084% |
ABBV AbbVie Inc. | 7,003 | $972,123.58 | $2.01M | - | $1.03M | 106.37% | +1.083% |
ABT Abbott Laboratories | 1,524 | $209,418.51 | $160,141.92 | - | -$49,276.59 | -23.53% | +0.382% |
ACB Aurora Cannabis Inc. | 7 | $31 | $28 | - | -$3 | -9.68% | -2.439% |
ACWV iShares MSCI Global Minimum Volatility ETF | 58,709 | $6.28M | $7.5M | - | $1.22M | 19.5% | +0.428% |
AEE Ameren Corporation | 107 | $9,448.38 | $11,267.1 | - | $1,818.72 | 19.25% | +1.484% |
AEP American Electric Power Company, Inc. | 869 | $77,508.19 | $109,902.43 | - | $32,394.24 | 41.79% | +1.754% |
AIZ Assurant Inc. | 2,251 | $423,729 | $642,480.42 | - | $218,751.42 | 51.63% | +1.259% |
ALNY Alnylam Pharmaceuticals Inc | 14 | $2,375 | $3,315.27 | - | $940.27 | 39.59% | +1.186% |
AMAT Applied Materials, Inc. | 5,209 | $818,289.11 | $2.17M | - | $1.35M | 165.31% | -3.077% |
AMD Advanced Micro Devices, Inc. | 30 | $4,317 | $16,259.1 | - | $11,942.1 | 276.63% | -3.604% |
AMGN Amgen Inc. | 71 | $16,197.42 | $31,120.72 | - | $14,923.3 | 92.13% | +0.988% |
AMT American Tower Corporation | 68 | $19,339.29 | $12,514.72 | - | -$6,824.57 | -35.29% | +1.478% |
AMZN Amazon.com Inc | 8,360 | $1.36M | $2.12M | - | $758,924.54 | 55.62% | -0.302% |
ARAY Accuray Incorporated | 181 | $864 | $30.26 | - | -$833.74 | -96.5% | -1.647% |
ATI ATI Inc. | 800 | $31,568 | $150,624 | - | $119,056 | 377.14% | -0.544% |
AVGO Broadcom Inc. | 2,120 | $653,342.01 | $712,532 | - | $59,189.99 | 9.06% | -2.39% |
AXP American Express Company | 162 | $37,411.52 | $51,793.02 | - | $14,381.5 | 38.44% | +1.861% |
BA Boeing Company | 105 | $18,585 | $20,005.65 | - | $1,420.65 | 7.64% | +0.954% |
BAC Bank of America Corporation | 4,636 | $184,711.07 | $243,135.02 | - | $58,423.95 | 31.63% | +1.441% |